Building the drug asset marketplace of the future by
empowering biopharma companies to accelerate drug pipelines and maximize return on investment, ensuring healthcare innovations reach their full commercial potential and patient impact.
preparing the sell-side to showcase the value of their assets effectively during portfolio strategy planning and dealmaking.
enabling institutional investors in making data driven decisions for capital allocation in drug asset transactions.
Our Offerings
The Prudentia Platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development.
Value Simulation
Portfolio Optimization
AI-Powered Scientific Evaluation
Dynamic Asset Staging
Expert in-the- loop Augmentation
Enterprise Platform
Rapid AI-powered synthesis of data room into an asset assessment framework and product profile enables comparison with public and proprietary data and benchmarks to determine asset risks and value drivers.
Multi-disciplinary expert in-the-loop deal analysis and modeling with real time analytics to enable AI-accelerated insight across multiple dimensions of asset value and risk.
Real-time data driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput.
AI-Guided product profiles and asset valuations to guide portfolio strategy and decision making.
Real-time data driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput.
Transparent and Traceable AI
Evidence-based insights
Comprehensive Audit Trails
SOC 2 Compliant
Customer-level Data Isolation
Advanced Data Encryption
Granular Access Control
Challenges Facing our Industry
In the life sciences sector, over $1 trillion in capital awaits investment opportunities annually.
Due diligence of science is manual, multidisciplinary, complex and resource intensive.
Many blockbuster drugs are losing exclusivity, intensifying the need for innovative deal structures.
Manual information assembly hinders holistic decision making.
Decision-makers need better tools to reduce risks, accelerate timelines, increase throughput, and make informed investments.
A persistent disconnect between scientific potential, clinical reality, and financial valuation.
Why Prudentia Sciences
We’re here to redefine biopharma asset identification, diligence, and valuation processes, ensuring your team stays ahead in a competitive and rapidly evolving market.
Expand capacity and resources to review more deals.
Improve collaboration with domain experts across R&D, clinical ops, and commercials across an organization.
Understand and maximize value drivers for assets.
Allocate capital efficiently by leveraging detailed insights.
Produce term sheets faster to analyze and close deals quickly.
Access industry experts and analytics at any time to evaluate the best investments.
DIFFERENTIATOR
“Our platform is designed to unlock the full potential of drug development and commercialization, ensuring that every dollar spent is optimized for impact.”
.png)
.png)
.png)
.png)
.png)
